SCHEDULE 13G/A: BML Investment Partners Discloses 6.55% Stake in Oramed Pharmaceuticals Inc.
Beneficial Ownership Report
BML Investment Partners, L.P. has reported a 6.55% beneficial ownership stake in Oramed Pharmaceuticals Inc., holding 2,643,907 shares of common stock as of December 31, 2024.
Summary
- BML Investment Partners, L.P. has filed an Amendment No. 1 to Schedule 13G, disclosing its beneficial ownership in Oramed Pharmaceuticals Inc.
- As of December 31, 2024, BML Investment Partners, L.P. beneficially owns 2,643,907 shares of Oramed Pharmaceuticals Inc. common stock.
- This ownership represents 6.55% of the total class of common stock.
- BML Investment Partners, L.P. holds shared voting power and shared dispositive power over all 2,643,907 shares.
- The filing certifies that the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer, indicating a passive investment.
Sentiment
Score: 5
Explanation: The document is a factual disclosure of beneficial ownership, which is neutral in tone. While a significant stake can be interpreted positively by the market, the document itself does not express sentiment.
Positives
- The disclosure of a significant stake (6.55%) by an institutional investor like BML Investment Partners, L.P. may signal increased institutional interest or confidence in Oramed Pharmaceuticals Inc.
Future Outlook
This Schedule 13G filing is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance regarding the issuer's future outlook.
Industry Context
This filing is a standard disclosure required when an investor acquires beneficial ownership of more than 5% of a company's voting class of securities. It reflects an investment firm's position in a publicly traded pharmaceutical company, a common occurrence in the financial markets.
Stakeholder Impact
- Shareholders: Provides transparency regarding significant ownership stakes, which can influence market perception and trading activity.
- Investment Professionals: Offers insight into institutional investment trends and specific holdings.
Key Dates
| Date | Description |
|---|---|
| 12/31/2024 | Date of event which requires the filing of this statement (reporting period end date) |
| 02/13/2025 | Date the Schedule 13G Amendment No. 1 was signed and filed |
Keywords
Oramed Pharmaceuticals, BML Investment Partners, Schedule 13G, Beneficial Ownership, Common Stock, SEC Filing, Institutional Investment
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.